# Liminatus Pharma Inc. (LIMN) Source: https://www.quantisnow.com/company/LIMN Generated: 2026-11-13T14:53:08.965Z - Ticker: LIMN - Exchange: NASDAQ - Sector: Health Care - Industry: Biotechnology: Biological Products (No Diagnostic Substances) - SEC CIK: 0001971387 ## Latest LIMN news and filings - 2026-11-03 21:15 UTC [SEC Form 8-K] [Liminatus Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits](https://www.quantisnow.com/insight/liminatus-pharma-inc-filed-sec-form-8-k-entry-into-a-6769857) - 2026-09-29 13:15 UTC [SEC Form 8-K] [Liminatus Pharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/liminatus-pharma-inc-filed-sec-form-8-k-notice-of-delisting-6728844) - 2026-09-29 13:00 UTC [Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule](https://www.quantisnow.com/insight/liminatus-pharma-regains-compliance-with-nasdaq-minimum-bid-price-rule-6728769) - 2026-08-24 12:00 UTC [Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy](https://www.quantisnow.com/insight/liminatus-pharma-engages-synex-as-contract-research-organization-to-support-6692107) - 2026-08-18 20:06 UTC [SEC Form 8-K] [Liminatus Pharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure](https://www.quantisnow.com/insight/liminatus-pharma-inc-filed-sec-form-8-k-notice-of-delisting-6686525) - 2026-08-18 20:01 UTC [Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock](https://www.quantisnow.com/insight/liminatus-pharma-inc-announces-reverse-stock-split-of-its-common-6686409) - 2026-08-14 20:51 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Liminatus Pharma Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-liminatus-pharma-inc-6683480) - 2026-08-13 11:15 UTC [Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement](https://www.quantisnow.com/insight/liminatus-pharma-announces-transfer-to-nasdaq-capital-market-and-extension-6679237) - 2026-08-04 20:30 UTC [SEC Form 8-K] [Liminatus Pharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/liminatus-pharma-inc-filed-sec-form-8-k-submission-of-matters-6662638) - 2026-07-30 01:49 UTC [SEC Form 8-K] [Liminatus Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/liminatus-pharma-inc-filed-sec-form-8-k-other-events-financial-6654627) - 2026-07-24 20:51 UTC [SEC Form 8-K] [Liminatus Pharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/liminatus-pharma-inc-filed-sec-form-8-k-notice-of-delisting-6648552) - 2026-07-14 21:46 UTC [SEC Form 4] [Large owner Valetudo Therapeutics Llc acquired 3,448,926 shares, increasing direct ownership by 192% to 5,244,351 units (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-valetudo-therapeutics-llc-acquired-3448926-shares-increasing-direct-6637179) - 2026-07-13 12:43 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Liminatus Pharma Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-liminatus-pharma-inc-6634940) - 2026-07-06 20:59 UTC [SEC Form 4] [Large owner Valetudo Therapeutics Llc disposed of 4,373,603 shares, decreasing direct ownership by 71% to 1,795,803 units (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-valetudo-therapeutics-llc-disposed-of-4373603-shares-decreasing-6628669) - 2026-07-06 20:57 UTC [SEC Form 3] [New insider Ewon Comfortech Co., Ltd. claimed ownership of 5,500,000 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-ewon-comfortech-co-ltd-claimed-ownership-of-5500000-6628662) - 2026-07-06 13:13 UTC [SEC Form 8-K] [Liminatus Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits](https://www.quantisnow.com/insight/liminatus-pharma-inc-filed-sec-form-8-k-entry-into-a-6627554) - 2026-06-30 20:30 UTC [Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline](https://www.quantisnow.com/insight/liminatus-pharma-amends-definitive-merger-agreement-with-innocsai-to-expand-6620985) - 2026-06-30 00:44 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by Liminatus Pharma Inc.](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-liminatus-pharma-inc-6619764) - 2026-06-24 01:28 UTC [SEC Form S-1] [SEC Form S-1 filed by Liminatus Pharma Inc.](https://www.quantisnow.com/insight/sec-form-s-1-filed-by-liminatus-pharma-inc-6613409) - 2026-06-18 20:15 UTC [SEC Form D] [SEC Form D filed by Liminatus Pharma Inc.](https://www.quantisnow.com/insight/sec-form-d-filed-by-liminatus-pharma-inc-6608761) - 2026-06-03 21:14 UTC [SEC Form 8-K] [Liminatus Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/liminatus-pharma-inc-filed-sec-form-8-k-entry-into-a-6587673) - 2026-06-03 12:33 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Liminatus Pharma Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-liminatus-pharma-inc-6586051) - 2026-06-03 12:30 UTC [Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds](https://www.quantisnow.com/insight/liminatus-pharma-enters-into-warrant-exercise-transaction-for-19-million-6586006) - 2026-05-27 20:30 UTC [SEC Form 8-K] [Liminatus Pharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits](https://www.quantisnow.com/insight/liminatus-pharma-inc-filed-sec-form-8-k-notice-of-delisting-6575104) - 2026-05-22 00:28 UTC [Liminatus Pharma Announces Nasdaq Delisting Notification](https://www.quantisnow.com/insight/liminatus-pharma-announces-nasdaq-delisting-notification-6568609) - 2026-05-21 12:04 UTC [Liminatus Pharma Announces Proposed Merger with InnocsAI to Expand Oncology Cell Therapy Pipeline](https://www.quantisnow.com/insight/liminatus-pharma-announces-proposed-merger-with-innocsai-to-expand-oncology-6566471) - 2026-05-20 21:00 UTC [SEC Form 8-K] [Liminatus Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits](https://www.quantisnow.com/insight/liminatus-pharma-inc-filed-sec-form-8-k-entry-into-a-6565647) - 2026-05-15 20:49 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Liminatus Pharma Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-liminatus-pharma-inc-6558140) - 2026-03-31 21:28 UTC [SEC Form 10-K] [SEC Form 10-K filed by Liminatus Pharma Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-liminatus-pharma-inc-6480063) - 2026-03-17 12:08 UTC [Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody](https://www.quantisnow.com/insight/liminatus-pharma-announces-planned-phase-1-clinical-trial-of-iba101-6451261) - 2026-03-04 21:15 UTC [SEC Form 8-K] [Liminatus Pharma Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits](https://www.quantisnow.com/insight/liminatus-pharma-inc-filed-sec-form-8-k-amendments-to-articles-6429516) - 2026-02-20 21:15 UTC [SEC Form SCHEDULE 13G filed by Liminatus Pharma Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-liminatus-pharma-inc-6404830) - 2026-02-18 22:13 UTC [SEC Form 8-K] [Liminatus Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/liminatus-pharma-inc-filed-sec-form-8-k-entry-into-a-6400261) - 2026-02-18 11:02 UTC [SEC Form 424B4 filed by Liminatus Pharma Inc.](https://www.quantisnow.com/insight/sec-form-424b4-filed-by-liminatus-pharma-inc-6397983) - 2026-02-17 13:44 UTC [Public Offering] [Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering](https://www.quantisnow.com/insight/liminatus-pharma-inc-announces-pricing-of-40-million-public-offering-6394658) - 2026-02-17 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Liminatus Pharma Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-liminatus-pharma-inc-6393940) - 2026-02-11 11:08 UTC [SEC Form S-1] [SEC Form S-1 filed by Liminatus Pharma Inc.](https://www.quantisnow.com/insight/sec-form-s-1-filed-by-liminatus-pharma-inc-6385433) - 2026-02-09 20:01 UTC [SEC Form 8-K] [Liminatus Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits](https://www.quantisnow.com/insight/liminatus-pharma-inc-filed-sec-form-8-k-entry-into-a-6381521) - 2026-01-26 21:31 UTC [SEC Form 8-K] [Liminatus Pharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits](https://www.quantisnow.com/insight/liminatus-pharma-inc-filed-sec-form-8-k-notice-of-delisting-6360834) - 2025-11-25 22:26 UTC [SEC Form 8-K] [Liminatus Pharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits](https://www.quantisnow.com/insight/liminatus-pharma-inc-filed-sec-form-8-k-notice-of-delisting-6294044) ## More - Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/LIMN - Earnings history: https://www.quantisnow.com/earnings/LIMN - Dividend history: https://www.quantisnow.com/dividends/LIMN - Insider transactions: https://www.quantisnow.com/insiders/LIMN - Options chain: https://www.quantisnow.com/options/LIMN - SEC 8-K filings only: https://www.quantisnow.com/company/LIMN/8-k - RSS and alerts for LIMN: https://www.quantisnow.com/docs/rss-feeds.md